Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

849
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

326
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
326
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

284
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
284
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

400
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
400
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Gupta et al. Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells. <i>Cancers</i> 2023, <i>15</i>, 2198.

Cancers·2024
Same author

Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells.

Cancers·2023
Same author

Nilotinib-Associated Destructive Thyroiditis.

Case reports in endocrinology·2015
Same author

Subclinical hyperthyroidism and cardiovascular risk: recommendations for treatment.

Cardiology in review·2013
Same author

Vitamin D and retinopathy in adults with diabetes mellitus.

Archives of ophthalmology (Chicago, Ill. : 1960)·2012
Same author

Tracking outpatient continuity and chronic disease indicators-a novel use of the new innovations clinic module.

American journal of therapeutics·2012

Related Experiment Video

Updated: Jan 1, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.1K

Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management.

Padma Raghavan Pillai1, Mindy Griffith, Monica D Schwarcz

  • 1From the Division of Endocrinology, Department of Medicine, Westchester Medical Center at New York Medical College, Valhalla, NY.

Cardiology in Review
|December 24, 2019
PubMed
Summary
This summary is machine-generated.

Primary aldosteronism is a common cause of secondary hypertension, posing diagnostic and management challenges. This review covers diagnosis, cardiovascular effects, and treatment options like medication and surgery, emphasizing a collaborative approach.

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.4K

Related Experiment Videos

Last Updated: Jan 1, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.1K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.4K

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Primary aldosteronism is a significant cause of secondary hypertension.
  • Diagnosis and management present ongoing clinical challenges.
  • Cardiovascular manifestations are a key concern.

Purpose of the Study:

  • To review the diagnostic approaches for primary aldosteronism.
  • To discuss the cardiovascular implications of the condition.
  • To outline current treatment strategies.

Main Methods:

  • Review of existing literature on primary aldosteronism.
  • Analysis of diagnostic algorithms and testing complexities.
  • Examination of treatment modalities including medical and surgical options.

Main Results:

  • Screening and diagnosis can be complex, particularly in confirming laterality.
  • Mineralocorticoid receptor antagonists and unilateral adrenalectomy are primary treatments.
  • A multidisciplinary approach is essential for effective patient care.

Conclusions:

  • Accurate diagnosis and management of primary aldosteronism require a comprehensive understanding of its complexities.
  • Effective treatment necessitates collaboration among various medical specialists.
  • Addressing primary aldosteronism is crucial for managing secondary hypertension and its cardiovascular sequelae.